Stem Cell Therapy Found Safe and Promising in Treating Parkinson’s Disease, Landmark Trials Show

TDT | Manama
Email : editor@newsofbahrain.com

Stem cell therapy has emerged as a safe and potentially game-changing treatment for Parkinson’s disease, according to the results of two major clinical trials published in the journal Nature.

The independent studies, conducted by research teams in Japan and the United States, demonstrate that stem cell-derived therapies can replenish dopamine-producing neurons in the brain — a critical factor in addressing the underlying cause of Parkinson’s disease.

🧠 A New Approach to a Complex Disease

Parkinson’s disease is a progressive neurodegenerative disorder marked by the loss of neurons that produce dopamine, a key neurotransmitter responsible for motor control. While current medications like ʟ-dopa offer temporary relief, they often lose effectiveness over time and cause side effects such as involuntary movements (dyskinesia).

The two new studies suggest that replacing damaged neurons with healthy, dopamine-producing cells derived from stem cells could offer a more sustainable and less intrusive solution.

🇯🇵 Japan Trial: No Major Side Effects, Promising Improvements

The first Phase I/II clinical trial, led by Kyoto University researchers, involved seven patients aged 50–69. These individuals received transplants of dopaminergic progenitor cells — derived from human induced pluripotent stem cells (iPSCs) — into both sides of their brains.

After 24 months of monitoring, no serious adverse events were reported. The transplanted cells successfully produced dopamine without forming tumors or growing uncontrollably — two major safety concerns in stem cell therapy.

Motor symptoms improved in four of the six patients who completed the efficacy evaluation without medication, and in five when standard Parkinson’s medications were administered.

🇺🇸 US Trial: Stem Cells Show Strong Safety Profile

The second Phase I trial, conducted by Memorial Sloan Kettering Cancer Center in the US, tested a stem cell product known as bemdaneprocel, derived from human embryonic stem cells. Twelve patients with a median age of 67 underwent surgical transplantation of the cells into the putamen, a key area in the brain affected by Parkinson’s.

Participants were divided into low-dose (five patients) and high-dose (seven patients) groups. Over 18 months, the therapy was well tolerated with no severe side effects or dyskinesia. Both groups also experienced some motor function improvement.

🧬 What’s Next?

Despite the small sample sizes, both studies mark a critical step toward establishing stem cell therapy as a viable treatment for Parkinson’s disease. Researchers emphasize the need for larger trials to further assess long-term benefits and confirm efficacy.

“This is an important step toward making cell therapy a standard treatment for Parkinson’s,” the researchers stated. “But larger studies will be essential to fully establish its clinical potential.”

These findings renew hope for millions living with Parkinson’s and signal a shift toward regenerative medicine as a future standard of care.